Loading...
XSHG600671
Market cap150mUSD
Dec 23, Last price  
9.00CNY
1D
-4.86%
1Q
33.33%
Jan 2017
-70.79%
Name

Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd

Chart & Performance

D1W1MN
XSHG:600671 chart
P/E
—
P/S
9.00
EPS
—
Div Yield, %
0.61%
Shrs. gr., 5y
-0.27%
Rev. gr., 5y
-19.42%
Revenues
122m
+11.82%
209,710,405238,707,452259,671,298265,228,863253,978,179245,336,892234,226,890277,265,339229,078,895281,468,861148,727,33894,765,832123,725,458176,382,787358,470,846297,072,374206,627,323147,069,186108,906,179121,778,535
Net income
-38m
6,903,3993,671,008386,43015,120,9894,079,5180026,439,20702,108,4202,713,42801,217,1847,179,075050,680,106000-38,275,148
CFO
-20m
1,354,2608,482,67555,387,26847,532,66521,189,1807,583,47500012,372,830653,79001,606,84924,520,31970,706,116161,127,708000-20,428,820
Dividend
Aug 24, 20050.163768 CNY/sh
Earnings
May 20, 2025

Profile

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd, together with its subsidiaries, engages in the pharmaceutical manufacturing and drug distribution businesses in China. The company produces and sells medicines and related health care products, including tablets, granules, pills, mixtures, oral liquids, syrups, eye drops, pills, soft capsules, tablets, granules, and other health foods. It is also involved in the sale of menthol and peppermint oil raw materials, Chinese medicine formulas, Chinese medicine pieces, fresh herbs, etc.; and provision of professional medical services, such as valet decoction and distribution, slicing, and powder grinding services, as well as Chinese medicine diagnosis and treatment services. In addition, the company engages in the software development, remote health management, commercial complex management, food, Internet information businesses, etc. Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd was founded in 1958 and is headquartered in Hangzhou, China.
URL
http://www.hztmyy.com/
IPO date
Aug 23, 1993
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
121,779
11.82%
108,906
-25.95%
147,069
-28.82%
Cost of revenue
115,061
103,758
139,625
Unusual Expense (Income)
NOPBT
6,717
5,148
7,444
NOPBT Margin
5.52%
4.73%
5.06%
Operating Taxes
2,985
842
Tax Rate
44.44%
16.36%
NOPAT
3,732
4,306
7,444
Net income
(38,275)
 
Dividends
(6,665)
Dividend yield
0.47%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
102,639
108,541
108,208
Long-term debt
14,463
14,926
9,103
Deferred revenue
58,616
65,246
78,706
Other long-term liabilities
1,148
1,430
3,682
Net debt
19,140
81,075
95,019
Cash flow
Cash from operating activities
(20,429)
CAPEX
(8,956)
Cash from investing activities
(8,826)
Cash from financing activities
84,825
56,056
34,520
FCF
17,006
60,025
64,218
Balance
Cash
97,963
42,392
22,291
Long term investments
2
2
2
Excess cash
91,874
36,947
14,938
Stockholders' equity
(131,021)
191,959
184,477
Invested Capital
356,604
147,781
240,697
ROIC
1.48%
2.22%
2.72%
ROCE
2.94%
2.79%
2.91%
EV
Common stock shares outstanding
121,779
121,779
121,779
Price
11.65
22.50%
9.51
5.90%
8.98
4.30%
Market cap
1,418,726
22.50%
1,158,117
5.90%
1,093,574
4.30%
EV
1,456,676
1,258,299
1,207,968
EBITDA
21,731
23,493
19,748
EV/EBITDA
67.03
53.56
61.17
Interest
7,244
7,404
7,351
Interest/NOPBT
107.84%
143.84%
98.76%